VIMTALABSVimta Labs Ltd.

₹713+0.57%

Market Cap

₹3,160.62 Cr

Stock P/E

51.50

ROCE

17.81%

ROE

13.94%

Book Value

₹81.89

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
Record quarterly revenue, marking the highest ever quarterly revenue and signaling strong growth momentum.
•
Quality credentials and regulatory progress bolster credibility (US FDA GCP inspection completed with no Form 483 observations).

NEGATIVES

•
Potential EBITDA/margin pressure from new capex and ongoing cost pressures.
•
Tariff risks could impact exports, adding a potential external headwind.

Peers Summary

Sector Leader

Vimta Labs Ltd. shows solid growth and efficiency metrics compared to its peers in the Pharmaceuticals & Drugs sector. It has a moderate valuation with a relatively low debt level, positioning it favorably against companies that are either overvalued or financially stressed. The analysis identifies key outperformers and potential value picks within the sector, highlighting Vimta as a robust competitor.

Key Points

• Vimta Labs shows strong revenue growth over 3 years at 14.74% and solid profitability with a ROE of 13.94%.
• Cipla Ltd. emerges as the most attractive value pick due to its low PE ratio of 23.73 and high ROE of 16.63%.
• Divi's Laboratories, while showing revenue growth, has the highest PE ratio of 73.20, indicating it may be overvalued compared to its performance.

Top Performers

Cipla Ltd.

Lowest PE ratio (23.73) and high ROE (16.63%), indicating strong profitability at a reasonable valuation.

Dr. Reddy's Laboratories Ltd.

High profitability metrics with an ROE of 21.76% and a low PE ratio of 15.50, making it attractive.

Mankind Pharma Ltd.

Strong revenue growth (18.12% YoY) and solid ROE (23.15%) with a manageable debt level.

Explore

Watchlists

Command Palette